SCHEMBL7085605

SCHEMBL7085605

O=Cc1ccc(N(Cc2ccccc2)Cc2ccccc2)cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 1/20 0.45
SLC16A1 P53985 1/20 0.45
CYP2C19 P33261 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
NR1H2 P55055 2/20 0.41
NR1H3 Q13133 2/20 0.41
ALDH1A1 P00352 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NR3C1 P04150 2/20 0.40
S1PR1 P21453 2/20 0.40
QPCT Q16769 1/20 0.40
PTPN1 P18031 1/20 0.40
TSHR P16473 1/20 0.39
CYP1A2 P05177 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27978827 0.83 CYP2C19 (0.46) SLC16A3SLC16A1CYP2C19TDP1CRHBP
SCHEMBL1199323 0.81 CYP2C19 (0.53) SLC16A3SLC16A1CYP2C19CRHBPCRHR2
SCHEMBL10845500 0.81 SLC16A3 (0.48) SLC16A3SLC16A1CYP2C19TDP1CRHBP
SCHEMBL24132784 0.81 CYP2C19 (0.43) CYP2C19TDP1CRHBPCRHR2NR1H2
SCHEMBL10791087 0.80 BACE1 (0.48) SLC16A3SLC16A1CYP2C19TDP1CRHBP
SCHEMBL10790440 0.79 ALDH1A1 (0.52) SLC16A3SLC16A1CYP2C19CRHBPCRHR2
SCHEMBL10787489 0.78 CYP2C19 (0.53) SLC16A3SLC16A1CYP2C19CRHBPCRHR2
SCHEMBL9733725 0.77 ALDH1A1 (0.66) CYP2C19TDP1CRHBPCRHR2ALDH1A1
SCHEMBL11792164 0.77 PTGS2 (0.45) SLC16A3SLC16A1CYP2C19CRHBPCRHR2
SCHEMBL10787437 0.76 ALDH1A1 (0.50) SLC16A3SLC16A1CYP2C19CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them MERCK PATENT GMBH (DE) 2003-09-11 US disclosed
US-6559185-B2 Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use MERCK PATENT GMBH (DE) 2003-05-06 US disclosed
US-20030069312-A1 Antidiabetic agents LARDY CLAUDE (FR) 2003-04-10 US disclosed
US-6043281-A ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-03-28 US disclosed
EP-0983226-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GmbH (DE) 2000-03-08 EP disclosed
WO-1998052906-A1 NEW NITROMETHYL KETONES, PROCESS FOR PREPARING THEM AND COMPOSITIONS CONTAINING THEM MERCK PATENT GMBH (DE) 1998-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069312-A1 Antidiabetic agents SLC5A1, SLC5A2, GPR119 SLC16A3 1140/4885SLC16A1 1138/4885CYP2C19 976/4885
US-20030171422-A1 New nitromethyl ketones, process for preparing them and compositions containing them AKR1B1, AKR1A1, AKR1C1 SLC16A3 3258/4885SLC16A1 3123/4885CYP2C19 612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.